

## **Genomtec sums up an intense 2024 and announces further development plans**

**Genomtec SA, a leading molecular diagnostics company headquartered in Wrocław (WSE ticker: GMT), has published a report summarizing its activities in 2024 – a period of intensive development and strategic activities.**

Last year, the Company focused on the development of the OncoSNAAT project focused on oncological diagnostics. The research focused on the detection of single nucleotide (SNP) changes using LAMP technology. Work related to sample optimization, in turn, brings the Company closer to the implementation of the main idea of OncoSNAAT, which is the use of only liquid biopsy, which for patients means limiting the test to blood collection and thus getting rid of the need to collect biopsies in the form of tumor lesions. Genomtec also began work on methods for isolating and concentrating genetic material, preparing to develop the full specification of the OncoSNAAT microfluidic diagnostic card, which will become an integral part of the diagnostic platform dedicated to oncological tests.

In parallel, recertification clinical trials of the Genomtec ID platform were conducted in France and Poland. The completion of the studies was postponed due to difficulties in obtaining positive samples for atypical bacteria, one of the five pathogens tested. However, Genomtec emphasizes that the deadline for the new registration regime for medical devices changed by the European Commission (postponed to the end of 2029) provides adequate time for full implementation of the new regulatory requirements, and until then the certification already held by GenomtecID will be valid.

*"Our business development activities in the field of acquiring an M&A partner were intensive in 2024. We participated in the world's most important industry conferences and conducted direct dialogue with potential partners. We have signed non-disclosure agreements (NDA) with them and are conducting advanced negotiations regarding the commercialization of our projects. These include companies located in the USA, including those listed on the NASDAQ market, large players in the field of clinical diagnostics, biotechnology and the pharmaceutical market. We are in ongoing dialogue with the R&D teams of potential partners - we receive inquiries and tasks from them, to which we respond, among others, by conducting work in the field of molecular biology and analyzer" -***comments Miron Tokarski, co-founder, shareholder and CEO of Genomtec S.A.**

In response to growing interest from potential partners in both Genomtec ID and the OncoSNAAT project, the Company has decided to spin off the projects into separate entities. This process aims to increase the investment attractiveness of both ventures and flexibility in further talks with partners.

*"At the end of the year, we began the process of spinning off projects into separate special purpose vehicles, which will allow us to offer them to different groups of investors. This structure increases transaction flexibility, enables better alignment with the expectations of M&A partners and*

*strengthens the strategic positioning of projects in the most promising market segments. We are considering various commercialization options - from licensing, through the sale of separated parts of the business, to the potential sale of the entire Genomtec company - and all actions taken are aimed at maximizing value for our shareholders"*— **says Michał Wachowski, Member of the Management Board and CFO of Genomtec S.A.**

The separation of the special purpose vehicles was preceded by obtaining a preliminary decision from PARP as a grantor in one of the company's projects. Genomtec also received a positive tax interpretation, which states that the contribution, as a capital contribution to the special purpose vehicles, of tangible and intangible assets related to the Genomtec ID project and the OncoSNAAT project, will be tax neutral for the company. Genomtec is still waiting for the NCBR decision regarding the separation of the special purpose vehicles. The process of contributing assets to the special purpose vehicles will be subject to approval by shareholders at the General Meeting of the Company.

In addition to cooperation with M&A advisor Clairfield Partners (for Genomtec ID), Genomtec has entered into an agreement with international advisory firm Lynx Financial, active in Asian markets, which supports the company in the process of selling the oncology project OncoSNAAT and commercialization of innovative diagnostic solutions.

At the end of 2024, Genomtec had financial resources of approximately PLN 7 million, which were additionally increased by approximately PLN 11 million from a new share issue in the first quarter of 2025. The stable financial situation of the Company is also supported by a grant from PARP, valid until 2027, from which expenditures are planned for the development of research infrastructure and cooperation with subcontractors in 2025–2026.

### **Webinar with the Genomtec Management Board**

On May 9 (Friday) at 12:00 there will be a meeting devoted to summarizing the development of Genomtec in 2024 and prospects for the following quarters. The meeting will be attended by: Miron Tokarski - President of the Management Board, Michał Wachowski - Member of the Management Board, CFO.

Online meeting, at the link\*: <https://ccgroup.clickmeeting.com/genomtec-sa-wyniki-fy-2024/register>

*\*registration for the meeting is required - you will receive an e-mail with an individual access link*

---

### **About Genomtec:**

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to engage qualified laboratory personnel. The solution uses microfluidic technology and proprietary, patented isothermal technology SNAAT®. Genomtec technology is protected by 12 patents, including in Europe, the USA and Japan, and the Company has 35 patent applications pending.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The company's headquarters is located in Wrocław. Genomtec also has a branch in Great Britain, where part of the international research and engineering team is located.



More information is available on the company's website: [www.genomtec.com](http://www.genomtec.com)

**Media contact:**

Michał Wierzchowski

Tel.: +48 531 613 067

[michal.wierzchowski@ccgroup.pl](mailto:michal.wierzchowski@ccgroup.pl)

**Contact for investors:**

Agata Dzieciołowska

Tel.: +48 606 205 119

[agata.dzieciolowska@ccgroup.pl](mailto:agata.dzieciolowska@ccgroup.pl)